Yakult extends Proacta alliance to another anticancer prodrug

Japan's Yakult Honsha has expanded a collaborative R&D and commercialisation agreement with Proacta to include another of the private US firm's hypoxia-activated prodrugs for cancer.

Japan's Yakult Honsha has expanded a collaborative R&D and commercialisation agreement with Proacta to include another of the private US firm's hypoxia-activated prodrugs for cancer.

Yakult acquired exclusive development and commercialisation rights in Japan to Proacta's irreversible multi-kinase inhibitor (MKI) PR509 earlier this year (

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapeutic Category